Table 1.

Status of Clinical Trials Network clinical trials (December 2010)

Protocol # (Referencea)	Principal Investigator	Study	Sites	N	Status
CTN 0001	Ling	Buprenorphine/naloxone for inpatient detoxification	6	113	Completed (Ling 2005)37
CTN 0002	Ling	Buprenorphine/naloxone for outpatient detoxification	6	230	Completed (Ling 2005)37
CTN 0003	Ling	Comparison of two buprenorphine/naloxone taper schedules	11	516	Completed (Ling 2009)38
CTN 0004	Carroll	Motivational enhancement therapy for patients in treatment for substance use disorders	6	496	Completed (Ball 2007)39
CTN 0005	Carroll	Motivational interviewing for patients in treatment for substance use disorders	5	423	Completed (Carroll 2006)40
CTN 0006	Stitzer	Low cost motivational incentives for stimulant-abusing patients in outpatient psychosocial treatment programs	8	454	Completed (Petry 2005)28
CTN 0007	Stitzer	Low cost motivational incentives for stimulant-abusing patients in methadone maintenance treatment	6	403	Completed (Peirce 2006)27
CTN 0009	Reid	Incorporating smoking cessation treatment into substance abuse treatment programs	12	225	Completed (Reid 2008)41
CTN 0010	Woody	Buprenorphine/naloxone-facilitated rehabilitation for opioid-dependent adolescents and young adults	6	154	Completed (Woody 2008)42
CTN 0011	Hubbard	Telephone enhancement procedure for long-term engagement in continuing care	4	339	Completed (Hubbard 2007)43
CTN 0013	Winhusen	Motivational enhancement therapy for pregnant women in treatment for substance use disorders	4	200	Completed (Winhusen 2008)44
CTN 0014	Szapocznik, Robbins	Brief Strategic Family Therapy for adolescents in treatment for substance use disorders	8	457	Manuscript in preparation
CTN 0015	Hien	Seeking Safety therapy for women with PTSD in treatment for substance use disorders	7	353	Completed (Hien 2009)45
CTN 0017	Booth	HIV/HCV risk reduction interventions for injection substance users	8	632	Completed (Booth 2010)46
CTN 0018	Calsyn	HIV/STD risk reduction interventions for men in treatment for substance use disorders	14	594	Completed (Calsyn 2009)47
CTN 0019	Tross	HIV/STD risk reduction interventions for women in treatment for substance use disorders	12	517	Completed (Tross 2008)48
CTN 0020	Svikis	Job seekers training for patients in treatment for substance use disorders	12	628	Manuscript in preparation
CTN 0021	Carroll, Szapocznik	Motivational enhancement therapy for Spanish-speaking patients in treatment for substance use disorders	6	463	Completed (Carroll 2009)49
CTN 0027	Ling	Liver function in patients maintained on buprenorphine/naloxone or methadone	9	1269	Manuscript in preparation
CTN 0028	Riggs, Winhusen	Osmotic-release methylphenidate for ADHD in adolescents in treatment for substance use disorders	11	303	Manuscript in preparation
CTN 0029	Somoza, Winhusen	Osmotic-release methylphenidate for ADHD in patients receiving smoking cessation treatment	6	255	Completed (Winhusen 2010)50
CTN 0030	Ling, Weiss	Treatment of prescription opioid addiction	11	653	Manuscript in preparation
CTN 0031	Donovan	Twelve-step engagement for patients in treatment for stimulant use disorders	10	471	Manuscript in preparation
CTN 0032	Metsch	HIV rapid testing and counseling in substance abuse treatment programs	12	1281	Manuscript in preparation
CTN 0037	Trivedi	Exercise as an adjunctive treatment for substance use disorders	9	330b	Enrolling
CTN 0044	Nunes	Web-delivered treatment for substance use disorders	10	500b	Enrolling
CTN 0046	Winhusen	Smoking cessation intervention for patients in treatment for stimulant use disorders	12	528b	Enrolling
CTN 0047	Bogenschutz, Donovan	Screening, motivational assessment, referral, and treatment in emergency departments	6	1285b	Enrolling
CTN 0048	Ling	Buprenorphine and naltrexone for treatment of cocaine dependence	12b	300b	Development
CTN 0049	Metsch	Linkage-to-care interventions for HIV-infected substance-using hospital inpatients	10b	800b	Development

Notes:

^aSee References for full citation;

^bPlanned study parameters.

Abbreviations: HIV, human immunodeficiency virus; HCV, hepatitis C virus; STD, sexually transmitted disease; PTSD, posttraumatic stress disorder; ADHD, attention deficit hyperactivity disorder.